文献速递妇科

曲美替尼用于复发性低级别浆液性卵巢癌的成本效果分析

Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
PubMed 文献 · Gynecol Oncol · 2022-11-08

基于GOG 281/LOGS试验,采用马尔可夫模型从美国支付方视角评估曲美替尼对比标准治疗用于复发性低级别浆液性卵巢癌的成本效果。曲美替尼组额外获得0.58个质量调整生命年(QALYs)和1.14个生命年(LYs),增量成本为248,214美元,增量成本效果比为424,097美元/QALY。在150,000美元/QALY的意愿支付阈值下,曲美替尼具有成本效果的概率为6%,结论为不具有成本效果。

要点

  • 曲美替尼组较标准治疗组额外获得0.58个QALYs和1.14个LYs。
  • 曲美替尼组增量成本为248,214美元,ICER为424,097美元/QALY。
  • 在150,000美元/QALY阈值下,曲美替尼具有成本效果的概率为6%。

核心结论

  • 从美国支付方视角,在假设的150,000美元/QALY意愿支付阈值下,曲美替尼对复发性低级别浆液性卵巢癌患者不具有成本效果。
  • 基于价值角度,曲美替尼降价有望改善其用于复发性低级别浆液性卵巢癌患者的成本效果。

研究设计与样本

  • 采用马尔可夫模型,从美国支付方视角比较曲美替尼组与标准治疗组在复发性低级别浆液性卵巢癌患者中的成本和效果。
  • 计算生命年(LYs)、质量调整生命年(QALYs)、终生成本和增量成本效果比(ICERs)。
  • 进行单因素分析和概率敏感性分析以探索模型稳健性。

主要发现

  • 曲美替尼组较标准治疗组额外获得0.58个QALYs(1.14个LYs),增量成本为248,214美元。
  • 增量成本效果比为424,097美元/QALY。
  • 单因素敏感性分析提示模型对曲美替尼组与标准治疗组之间OS和PFS的风险比、PFS的效用值以及曲美替尼的周期成本敏感。
  • 概率敏感性分析显示,在150,000美元/QALY的意愿支付阈值下,曲美替尼组具有成本效果的概率为6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The GOG 281/LOGS trial found that trametinib prolonged progression-free survival (PFS) in patients with recurrent low-grade serous ovarian cancer (LGSOC), compared with standard of care (SOC). The current study aimed to evaluate the cost-effectiveness of trametinib versus standard of care for recurrent LGSOC from the US payer perspective. METHODS: A Markov model was adopted to compare the cost and effectiveness of trametinib and standard of care group in patients with recurrent LGSOC. Life years (LYs), quality-adjusted LYs (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) were calculated. One-way, and probabilistic sensitivity analyses were performed to explore the model robustness. RESULT: Trametinib group provided an additional 0.58 QALYs (1.14 LYs) and an incremental cost of $248,214 compared with the SOC group. The incremental cost-effectiveness ratio was $424,097 per QALY. The results of one-way sensitivity analyses suggested that our model was sensitive to the hazard ratio of OS and PFS between trametinib and SOC group, utility of PFS and the cycle cost of trametinib. Probabilistic sensitivity analyses revealed that there was 6% probability of the trametinib group being cost-effective at a willingness-to-pay (WTP) threshold of $150,000 per QALY. CONCLUSIONS: From the US payer perspective, trametinib is not cost-effective for patients with recurrent LGSOC at the assumed WTP threshold of $150,000 per QALY. Based on the value standpoint, price reduction of trametinib is expected to improve the cost-effectiveness of trametinib in patients with recurrent LGSOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Piao H, Wu M, Qin S, et al. Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis. Gynecol Oncol. 2022. PMID: 36368128. doi:10.1016/j.ygyno.2022.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。